For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Sales of products and services | 0 | 0 | - | 867.5 |
| Cost of goods and services sold | 0 | 0 | - | 205.5 |
| Gross profit | 0 | 0 | - | 662 |
| Other operating expenses | - | - | 42,252 | 57,915.5 |
| Employee compensation | 192,869 | 183,864 | 205,800 | 229,708.5 |
| Occupancy | 46,920 | 49,723 | 174,624 | 52,607.5 |
| Depreciation and amortization of property and equipment | 41,893 | 41,744 | 41,263 | 41,236 |
| Amortization of intangible assets | 1,694 | 3,400 | 3,360 | 3,216 |
| Other operating expenses | 26,758 | -29,032 | - | - |
| Total operating expenses | 310,134 | 249,699 | 467,299 | 384,683.5 |
| Income (loss) from operations | -310,134 | -249,699 | -467,299 | -383,359.5 |
| Loss on obsolete inventory | 0 | 0 | - | -41,195 |
| Interest income (expense) | - | - | -19 | 43,359 |
| Interest expense | 18 | 23 | - | - |
| Total other income (expenses) | -18 | -23 | -19 | 2,164 |
| Loss before provision for income tax | -310,152 | -249,722 | -467,318 | -381,195.5 |
| Provision for income tax | 0 | 0 | - | - |
| Net loss | - | -249,722 | -467,318 | - |
| Net loss | -310,152 | -230,333 | -435,630 | -381,195.5 |
| Net loss attributable to non-controlling interest | -33,381 | -19,389 | -31,688 | -47,720.5 |
| Net loss attributable to common stockholders | -276,771 | - | - | -333,475 |
| Net loss per share basic and diluted | 0 | 0 | 0 | -0.003 |
| Weighted average common shares outstanding basic and diluted | 147,870,790 | 119,820,790 | 119,820,790 | 0 |
Yubo International Biotech Ltd (YBGJ)
Yubo International Biotech Ltd (YBGJ)